114080-93-2

Basic information

• Product Name: Isoxazolo[4,5-b]pyridin-3-amine (9CI)
• Synonyms: Isoxazolo[4,5-b]pyridin-3-amine (9CI);Isoxazolo[4,5-b]pyridin-3-amine;Isoxazolo[4,5-b]pyridin-3-ylaMine;3-AMino-isoxazolo[4,5-b]pyridine;[1,2]oxazolo[4,5-b]pyridin-3-amine
• CAS NO: 114080-93-2
• Molecular Formula: C₆H₅N₃O
• Molecular Weight: 135.1234
• Product Categories: PYRIDINE;organic building block
• Mol File: 114080-93-2.mol

Chemical Properties

• Boiling Point: 336.6°C at 760 mmHg
• Flash Point: 157.4°C
• Appearance: /
• Density: 1.421g/cm³
• Vapor Pressure: 0.000111mmHg at 25°C
• Refractive Index: 1.701
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: Isoxazolo[4,5-b]pyridin-3-amine (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Isoxazolo[4,5-b]pyridin-3-amine (9CI)(114080-93-2)
• EPA Substance Registry System: Isoxazolo[4,5-b]pyridin-3-amine (9CI)(114080-93-2)

Safety Data

• Hazardous Substances Data: 114080-93-2(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
Isoxazolo[4,5-b]pyridin-3-amine (9CI) is utilized as a key intermediate in the synthesis of pharmaceutical drugs. Its unique structure allows for the development of novel drug candidates with potential therapeutic applications in various medical fields.
Used in Organic Synthesis:
In the field of organic synthesis, Isoxazolo[4,5-b]pyridin-3-amine (9CI) serves as a valuable building block for the creation of complex organic molecules. Its reactivity and structural features facilitate the synthesis of a wide range of organic compounds with diverse applications.
Used in Chemical Research:
Isoxazolo[4,5-b]pyridin-3-amine (9CI) is employed as a research tool in chemical studies, enabling scientists to explore its properties, reactivity, and potential applications. Its unique structure and properties make it an interesting subject for further investigation and understanding of its role in chemical reactions and processes.

InChI:InChI=1/C6H5N3O/c7-6-5-4(10-9-6)2-1-3-8-5/h1-3H,(H2,7,9)

Upstream product

• 97509-75-6 3-fluoropicolinonitrile 
• 546-88-3 acetylhydroxamic acid 
• 38180-46-0 3-chloro-2-cyanopyridine 
• 1331937-25-7 3-hydroxypyrid-2-ylamidoxime 
• 68325-15-5 3-chloro-isonicotinonitrile 

Downstream Products

• 1230019-49-4 4-[3-(4-chloro-phenoxy)-benzyl]-piperazine-1-carboxylic acid isoxazolo[4,5-b]pyridin-3-ylamide 
• 1229383-76-9 isoxazolo[4,5-b]pyridin-3-yl-carbamic acid phenyl ester 

Relevant articles and documents

A high-yielding method for the preparation of isoxazolopyridin-3-amine derivatives

A highly efficient and green method has been developed for the rapid preparation of highly functionalized isoxazolopyridin-3-amine derivatives in excellent yields. This process has a broad substrate scope, is operationally simple, and generally requires no chromatographic purification. In addition, the process is scalable and significantly greener than current alternatives with a PMI of 18 and water as the reaction solvent.

Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation

The design, synthesis, and capacity to inhibit HIF prolyl 4-hydroxylases (PHDs) are described for 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide analogs. These analogs revealed two kinds of novel scaffolds as PHD2 inhibitors. Synthetic routes were

Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation

The design, synthesis, and capacity to inhibit HIF prolyl 4-hydroxylases (PHDs) are described for 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide analogs. These analogs revealed two kinds of novel scaffolds as PHD2 inhibitors. Synthetic routes were

Heteroaryl urea inhibitors of fatty acid amide hydrolase: Structure-mutagenicity relationships for arylamine metabolites

The structure-activity relationships for a series of heteroaryl urea inhibitors of fatty acid amide hydrolase (FAAH) are described. Members of this class of inhibitors have been shown to inactivate FAAH by covalent modification of an active site serine with subsequent release of an aromatic amine from the urea electrophile. Systematic Ames II testing guided the optimization of urea substituents by defining the structure-mutagenicity relationships for the released aromatic amine metabolites. Potent FAAH inhibitors were identified having heteroaryl amine leaving groups that were non-mutagenic in the Ames II assay.

Design, synthesis and evaluation of new α-nucleophiles for the hydrolysis of organophosphorus nerve agents: Application to the reactivation of phosphorylated acetylcholinesterase

A series of new α-nucleophiles including oximes and amidoximes have been synthesized, and their ability to efficiently and selectively cleave the P-S bond of organophosphorus nerve agents has been evaluated. The relationship between the chemical structure

SUBSTITUTED 3-AMINOISOXAZOLOPYRIDINES AS KCNQ2/3 MODULATORS

The invention relates to substituted 3-aminoisoxazolopyridines, to processes for their preparation, to medicaments containing these compounds and to the use of these compounds in the preparation of medicaments.

HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE

Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE

Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).